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Involvement of PPARa and PPARg in apoptosis and proliferation of
human hepatocarcinoma HepG2 cells
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Peroxisome proliferator-activated receptors (PPARs) mediate the effects of various ligands, known as peroxisome proliferators, a
heterogeneous class of compounds including industrial chemicals, pharmaceuticals, and biomolecules such as fatty acids and eicosanoids.
Among peroxisome proliferators, fibrate derivatives are considered specific ligands for PPARa, whereas eicosanoids, such as PGJ2, for
PPARg. The study aimed to clarify the relation between PPARs and apoptosis or proliferation on the same type of cells, using clofibrate as
specific ligand of PPARa and PGJ2 as specific ligand of PPARg. The cells used were human hepatocarcinoma HepG2 cells. The results
showed that PPARa protein content increased in HepG2 cells treated with clofibrate, causing apoptosis in a time- and concentration-
dependent way, as evidenced by the citofluorimetric assay and determination of BAD, myc and protein phosphatase 2A protein content. It also
emerged that PPARg increased in the same cells when treated with a specific ligand of this PPAR; in this case the increase of PPARg did not
cause an increase of apoptosis, but a time- and concentration-dependent inhibition of cell proliferation, evidenced by decreased cell numbers
and increased number of cells in the G0/G1 phase of the cycle. It may be concluded that PPARa is chiefly related to apoptosis and PPARg to
cell proliferation. Copyright # 2010 John Wiley & Sons, Ltd.
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INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) med-
iate the effects of various ligands, known as peroxisome
proliferators, a heterogeneous class of compounds including
industrial chemicals, pharmaceuticals, and biomolecules
such as fatty acids and eicosanoids. PPARs are a subgroup of
the nuclear hormone receptor superfamily, comprising three
molecular forms, namely PPARa, b/d, and g, that are
differentially expressed in adult and embryonic tissues.1 Upon
ligand binding, PPARs dimerize with retinoid receptors,
translocate to the nucleus, recognize specific PP-responsive
elements (PPRE) on DNA, and transactivate a number of
genes.2,3 PPARs are involved in the regulation of processes
such as intracellular lipid trafficking, mitochondrial and
peroxisomal fatty acid uptake and b-oxidation, inflammation,
cell proliferation, and death. In addition, depending on the
environment, it has been proposed that they act either as tumor
suppressors or as tumor promoters.4
Among peroxisome proliferators, fibrate derivatives are
considered specific ligands for PPARa, whereas eicosa-
noids, such as prostaglandin (PG)J2, are ligands for PPARg.
Fibrate derivatives include agents that have been and still are
widely used as hypolipidemic drugs, thanks to their ability to
lower plasma triglyceride levels by accelerating mitochon-
drial fatty acid b-oxidation through PPARa activation.5
Their administration to rats and mice causes peroxisome
proliferation, liver hypertrophy and hyperplasia, and
hepatocarcinogenesis;6,7 thus fibric acid derivatives, such
as clofibrate, have been widely employed in hepatocarci-
nogenesis protocols for rodents,8–10 in which its antiapop-
totic action is assumed to play an importantrole. On the
contrary, monkeys, pigs, and humans appear quite resistant
to such effects.11–13 Peroxisome proliferators are usually
regarded as non-genotoxic carcinogens, and their oncogeni-
city seems to depend on the oxidative stress caused by
peroxisome proliferation as well as on their ability to alter
the balance between cell proliferation and death.14,15 This
action is mediated through activation of PPARa, as shown
by studies reporting that PPARa-null mice are refractory to
hepatocarcinogenesis induced by administration of long-
term peroxisome proliferators.16
However, previous results from our laboratory have
demonstrated that treatment with clofibrate promptly
induces a massive and typical apoptosis in hepatocarcinoma
cells of both murine (Yoshida AH-130) and human origin
(HepG2).17 These observations have since been extended to
other peroxisome proliferators: nafenopin induces apoptotic
death in AH-130 cells,17 perfluorooctanoic acid and BR931
exert cytotoxic effects on the HepG2 hepatocarcinoma cell
line,18,19 and conjugated linoleic acid induces apoptotic
cell biochemistry and function
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death or inhibits cell proliferation depending on the degree
of malignancy of hepatic tumor cells.20,21 In addition, WY-
14 643 has been shown to enhance hepatocyte apoptosis in
mouse liver.21 Cytotoxicity or cell proliferation inhibition by
peroxisome proliferators is not restricted to cells of hepatic
origin, since similar effects have been observed in breast
and lung cancer cell lines20,22–25 as well as in human
keratinocytes and lymphoblasts.26,27 The effect of peroxi-
some proliferators on apoptosis or on cell proliferation may
be mediated by activation of PPARs. Ours previous results
appear to suggest that induction of PPARa is involved in
the effect of peroxisome proliferators on apoptosis, whereas
induction of PPARg is involved in the effect of peroxisome
proliferators on cell proliferation inhibition. For example,
clofibrate induced apoptosis in human keratinocytes through
induction of PPARa and inhibition of HMG-CoA reductase
(HMGR), a key enzyme in isoprenoid biosynthesis.26
Conjugated linoleic acid induced apoptotic death or
inhibited cell proliferation in several tumor cell lines,
respectively through PPARa or PPARg activation.20,21 On
the contrary, other studies have found that PPARg activation
triggers apoptosis both in vitro and in vivo. 28–30
The present study aimed to clarify the relation between
PPARs and apoptosis or proliferation on the same type of
cells, using clofibrate as specific ligand of PPARa, and PGJ2




Antibodies were purchased from Santa-Cruz Biotechnology,
Inc. (Santa Cruz, CA); MEM, fetal calf serum (FBS) from
Cambrex Corporation (East Rutherford, NJ), PGJ2 from
Cayman Chemical (Ann Arbor, MI); the other reagents from
Sigma (St. Louis, MO).
Cell cultures
Human hepatocarcinoma HepG2 cells (ATCC, Manassas,
VA, USA) were seeded (30 000 cells cm2) and maintained
for 24 h in MEM medium supplemented with 2mM
glutamine, 1% antibiotic/antimycotic solution, 1% non-
essential amino acids, and 10% FBS at 378C in a humidified
atmosphere of 95% air and 5% CO2.
Clofibrate treatment
Twenty-four hours after cell seeding, clofibrate dissolved
in DMSO (maximum final concentration 0.05%) was added
at concentrations of 0.25, 0.5, or 1mM. Control cells were
treated with vehicle alone. At the experimental times
indicated in the figures, cells treated or not with clofibrate
were trypsinized, harvested, and centrifuged at 600g for
10min in order to carry out the determinations described
below.
PGJ2 treatment
PGJ2 prepared in methylacetate was evaporated under
nitrogen and resuspended in DMSO at 3mM concentration.
Twenty-four hour after cell seeding, PGJ2 was added at
concentrations of 5 and 10mM. Control cells were treated
with vehicle alone. At the experimental times indicated in
the figures, cells treated or not with PGJ2 were trypsinized,
harvested and centrifuged at 600g for 10min in order to
carry out the determinations described below.
Cell proliferation
Cell proliferation was measured by counting the number of
cells present in the monolayer using a Bu¨rker chamber. The
trypan blue exclusion test for viability determination was
performed.
DNA content
After treatments, the percentage of cells showing an
hypodiploid content of DNA, typical of apoptotic cells
(sub G0/G1 peak), was evaluated by determining the DNA
content through propidium iodide staining, as described
elsewhere.31 Briefly, cells were washed in PBS, fixed in ice-
cold 70% ethanol for at least 30min, incubated at room
temperature in PBS containing DNase-free RNase (Type II-
A) and propidium iodide, respectively at final concentrations
of 0.4 and 0.18mgml1, then analyzed with a FACScan flow
cytometer (Becton & Dickinson, Mountain View, CA)
equipped with a 488 nm argon laser and two filters in
acquisition, respectively at 585 nm (FL2) and above 620 nm
(FL3). Data were recorded on a Macintosh Computer (G3),
using CellQuest software (BD Biosciences, Le Pont-De-
Claix Cedex France).
Western blot analysis
Collected cells were suspended to 50% (w/v) in HCMF
buffer containing 1% Triton, 0.1% SDS, 2mM CaCl2,
100mgml1 phenyl methyl sulfonyl fluoride, 1mgml1
leupeptin, and sonicated three times for 3 s. The extracted
proteins were used for Western blot analysis, as explained
elsewhere.32 Protein content was determined using the
Protein Assay Kit 2 (Bio-Rad Laboratory, Inc., Hercules,
CA).
Polyclonal anti-BAD, anti-c-myc, anti-protein phospha-
tase (PP) 2A, anti-PPARa and g antibodies, and monoclonal
anti-b-actin antibodies were used. Protein bands were
visualized through a chemiluminescence detection system
(Immun-StarTM HRP Luminol/Enhancer; Bio-Rad Labora-
tories, Inc.).
Statistical analysis
Data are expressed as means SD. The significance of
differences between group means was assessed by variance
analysis, followed by the post hoc Newman–Keuls test.
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RESULTS AND DISCUSSION
To demonstrate the different effect of PPARa and PPARg on
tumor cells, the same HepG2 cells were treated with two
different ligands of PPAR isoforms: clofibrate, which is
specific for the induction of PPARa, and PGJ2, which is
specific for PPARg.
Figure 1 summarizes the results regarding the growth
reduction determined by clofibrate treatment in HepG2 cells.
Note that 48 h clofibrate treatment caused a dose-dependent
decrease in cell numbers, corresponding, respectively, to 72,
70, and 36% of the control cells at 0.25, 0.5, and 1mM
concentrations. At the same experimental time, the number
of cells floating in the medium was equal to that of control
cells for 0.25mM concentration, and about 5 and 10 times
control values for the other two concentrations. To evaluate
the possible apoptotic effect of clofibrate, DNA content and
some pro-apoptotic proteins were analyzed.
Figure 2 shows the DNA content evaluated by flow
cytometric analysis: the percentage of cells in apoptosis
increased significantly in the presence of clofibrate concen-
trations at 24 and 48h, reaching an increase of about 3.5 times
versus controls at 48h with 0.5mM concentration.
Only the two lowest concentrations were used to analyze
some proteins involved in apoptosis. Figure 3 shows that
BAD (panel A), c-myc (panel B), and PP2A (panel C)
increased versus controls after 48 h treatment with 0.25 and
0.5mM. BAD is conventionally considered a marker of
apoptosis. The ability of Bad to promote apoptosis depends
upon its phosphorylation status; when dephosphorylated,
Figure 1. Number of cells present in monolayer and culture medium after treatment of HepG2 cells with clofibrate. Twenty-four hours after seeding, cells
were treated with different concentrations (mM) of clofibrate for periods ranging from 4–48 h. Control cells were treated with vehicle alone. The number of
cells cm2 counted in the monolayer or in the medium are represented as means SD of three experiments. Means with different letters are significantly
different from one another (P< 0.05) as determined by analysis of variance followed by the post hocNewman–Keuls test. C, control cells; CL 0.25, cells treated
with 0.25mM clofibrate; CL 0.5, cells treated with 0.5mM clofibrate; CL 1, cells treated with 1mM clofibrate.
Figure 2. Percentage of apoptotic cells present in the monolayer after treatment of HepG2 cells with clofibrate 24 h after seeding, cells were treated with
different concentrations (mM) of clofibrate for periods ranging from 4–48 h. Control cells were treated with vehicle alone. The percentage of apoptotic cells
determined by flow cytometric analysis are represented as means SD of three experiments. Means with different letters are significantly different from one
another (P< 0.05), as determined by analysis of variance followed by the post hoc Newman–Keuls test. C, control cells; CL 0.25, cells treated with 0.25mM
clofibrate; CL 0.5, cells treated with 0.5mM clofibrate.
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Bad is targeted to the mitochondria surface where it binds
Bcl-XL or Bcl-2, and causes cell death. Changes in Bad
phosphorylation occur rapidly in response to apoptotic
stimuli.33 Therefore, dephosphorylation is an essential
stage in apoptosis. The increase of PP2A protein content
is probably important in determining Bad dephosphoryla-
tion. In fact, PP2A plays a critical role in cellular physiology
including cell cycle regulation, cell proliferation and death,
development, cytoskeleton dynamics, cell mobility, and
regulation of multiple signal transduction pathways.34 The
results of this research agree with our previous data obtained
treating hepatocarcinoma SK-HEP-1 with conjugated
linoleic acid: in that experimental protocol the induced
PPARa increased PP2A causing apoptosis.21
The increase in c-myc observed in this research was
parallel to the increase in PPARa; this collaborates in
sensitizing cells to apoptosis, and agrees with our previous
observations that ciprofibrate- or clofibrate-induced apop-
tosis was coupled with increased content of PPARa and c-
myc in hepatoma cells and in keratinocytes, respect-
Figure 3. Effect of clofibrate on pro-apototic proteins (BAD, c-myc, PP2A) in HepG2 cells after 48 h of treatment. Protein content was evaluated by Western
blot analysis. The densitometry value associated with each protein band was normalized to the corresponding b-actin value and expressed as increasing times,
setting the control value (C) arbitrarily at 1. The arbitrary units are means SD of three experiments. Means with different letters are significantly different from
one another (P< 0.05), as determined by analysis of variance followed by the post hocNewman–Keuls test. C, control cells; CL 0.25, cells treated with 0.25mM
clofibrate; CL 0.5, cells treated with 0.5mM clofibrate.
Figure 4. Effect of clofibrate on PPARa and g protein content in HepG2 cells after 48 h of treatment. Protein content was evaluated by Western blot analysis.
The densitometry value associated with each protein band was normalized to the corresponding b-actin value and expressed as increasing times, setting the
control value (C) arbitrarily at 1. The arbitrary units are meansSD of three experiments. Means with different letters are significantly different from one
another (P< 0.05), as determined by analysis of variance followed by the post hoc Newman–Keuls test. C, control cells; CL 0.25, cells treated with 0.25mM
clofibrate; CL 0.5, cells treated with 0.5mM clofibrate.
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ively.27,35 The cellular oncogene c-myc encodes a nuclear
transcription factor involved in both normal and dysregu-
lated cell division, and/or in the apoptotic process. Some
studies36–38 have shown that the hepatic c-myc (or N-myc)
mRNA level is increased in rodents treated with peroxisome
proliferators, and that c-myc gene expression is dependent
on PPARa, since PPARa null mice were refractory to
induction of the c-myc oncogene in liver after treatment with
a peroxisome proliferator. Further support for a direct role
of PPARa in the regulation of c-myc gene expression
has been provided by the observation that the mouse N-myc
promoter contains a putative peroxisome proliferator response
element (PPRE).37 c-Myc can collaborate with other proteins
to induce apoptosis. In neuroblastoma cells, enforced N-myc
expression generally increases the susceptibility of neuro-
blastoma cells to a variety of death stimuli.38
Figure 5. Number of cells in monolayer and medium, percentage of viable, necrotic, and apoptotic cells, and percentage of cells in cell cycle phases, after
treatment with PGJ2 of HepG2 cells. Twenty-four hours after seeding, cells were treated with different concentrations (mM) of PGJ2 for a further 24 and 48 h.
Control cells were treated with vehicle alone. The number of cells cm2 counted in monolayer or medium, and the percentages of cells in cycle phases, are
represented as meansSD of three experiments. The SD of the percentage of cells in different cycle phases (not reported) was below 10%.Means with different
letters are significantly different from one another (P< 0.05) as determined by analysis of variance followed by the post hoc Newman–Keuls test. C, control
cells; PGJ 5, cells treated with 5mM PGJ2; PGJ 10, cells treated with 10mM PGJ2; PGJ 20, cells treated with 20mM PGJ2.
Figure 6. Effect of PGJ2 on PPARg protein content in HepG2 cells after 24 and 48 h of treatment. Protein content was evaluated byWestern blot analysis. The
densitometry value associated with each protein band was normalized to the corresponding b-actin value and expressed as increasing times, setting the control
value (C) arbitrarily at 1. The arbitrary units are meansSD of three experiments. For each PPARg isoform, means with different letters are significantly
different from one another (P< 0.05), as determined by analysis of variance followed by the post hoc Newman–Keuls test. C, control cells PGJ 5; cells treated
with 5mM PGJ2; PGJ 10, cells treated with 10mM PGJ2.
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The evaluation of PPARs showed (Figure 4) that an increase
of PPARa (panel A) was evident in the presence of both 0.25
and 0.5mM clofibrate at 48h in comparison with controls,
whereas PPARg (panel B) content did not show any increase.
This result further confirmed that PPARa is involved in the
induction of apoptosis, as hypothesized in the case of our results
with clofibrate on keratinocytes, reported elsewhere26 or with
conjugated linoleic acid on hepatoma SK-HEP-1 cells.21
To verify the different roles played by PPARa and g
in modulating tumor cell growth, HepG2 cells were treated
with PGJ2, a specific natural ligand of PPARg. 5 or 10mM
PGJ2 decreased cell numbers (Figure 5 panel A and B,),
whereas 20mM PGJ2 caused detachment of almost all
cells from the monolayer at 48 h treatment. Therefore, this
concentration was not used for the subsequent determi-
nations. In agreement with the fact that no cell detachment
was observed in the presence of 5 or 10mM PGJ2, flow
cytometry analysis showed that no changes in necrotic or
apoptotic cell numbers had occurred (panel C). The flow
cytometric analysis of the percentages of cells in the different
cell cycle phases (Figure 5, panel D) revealed that, in the
presence of 10mM PGJ2, the inhibition of cell growth was
coupled with a significant increase in the percentage of cells in
the G0/G1 phase (þ16%), and a significant decrease of S phase.
The decreased cell proliferation indicated by the decreased cell
numbers and increased cell percentage in the G0/G1 phase, was
accompanied by increased PPARg. Figure 6 shows the PPARg
protein content in PGJ2-treated cells; it may be seen that the
increase is time- and concentration-dependent. This confirms
other results obtained on different types of cells with other
PPARg-ligands.11,22,23,30
CONCLUSIONS
The results of this research confirm that the activation of
different PPAR isotypes triggers different intracellular transduc-
tion pathways, leading to apoptosis or to the block of cell
proliferation. In particular, it emerged that activation of PPARa
by clofibrate increases PP2A expression and, in consequence,
induces apoptosis by increasing the pro-apoptotic BAD. The
importance of this pathway in modulating cell survival had
previously been evidenced in hepatoma SK-HEP-1 cells treated
with CLA. We also confirm that, in human hepatoma cells,
activation of PPARg preferentially results in a reduction of cell
proliferation without inducing cell death. These observations
could be important in preparing and using PPAR ligands with
the aim of inducing specific effects in tumor cells.
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